Pacira Pharmaceuticals Price Target Raised to $59.00 at Brean Capital (PCRX)
Analysts at Brean Capital hoisted their price objective on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $44.00 to $59.00 in a research report issued to clients and investors on Thursday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Brean Capital’s price target indicates a potential upside of 12.08% from the stock’s previous close.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 0.44% on Thursday, hitting $52.64. 684,285 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a one year low of $15.07 and a one year high of $53.75. The stock has a 50-day moving average of $39.89 and a 200-day moving average of $32.66. The company’s market cap is $1.754 billion.
A number of other firms have also recently commented on PCRX. Analysts at Jefferies Group raised their EPS on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note to investors on Tuesday. They now have a “buy” rating and a $58.00 price target on the stock. They previously had a $44.00 price target on the stock. Separately, analysts at Barclays Capital raised their price target on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $40.00 to $43.00 in a research note to investors on Friday, September 20th. They now have an “overweight” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $51.40.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.